Why Is INDIVIOR PHARMACEUTI (INDV) Stock Down Today?
By the Top Tier Newswire AI Desk · August 3, 2026 at 10:30 AM ET · reviewed against 15 wire stories
INDIVIOR PHARMACEUTI (INDV) is down -4.66% in the latest session. Our newswire has captured 15 stories on INDV across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
INDV stock is down 4.66% to $38.15 as of the latest trade, following a sharp intraday reversal from a large opening gap up. The stock opened at $42.47, but quickly reversed course amid mixed reactions to the proposed merger between Indivior and Supernus Pharmaceuticals. The deal, announced in the past 36 hours, is a tax-free, stock-for-stock merger of equals expected to create a neuroscience-focused biopharmaceutical company.
What Happened
The merger announcement came alongside strong Q2 results for Indivior, including record SUBLOCADE sales and a 111% year-over-year increase in EBITDA. The company also raised its full-year revenue guidance to $1.295B, $1.365B. Supernus also announced a revenue beat and higher guidance, though it reported an earnings miss due to a non-cash impairment charge. Despite these positive developments, the stock opened with a 6.1% gap up and then declined throughout the session, reaching a low of $37.86. The sharp intraday reversal suggests uncertainty among traders about the merger’s valuation and integration risks.
What The Data Shows
The session volume of 1.3 million shares is 0.7 times the 3-month average, indicating a relatively muted response to the news. The stock has traded between $19.31 and $42.81 over the past 52 weeks. Recent insider transactions show three sales totaling $2.8 million in the last 90 days. Congressional trades in the same period include two buys and two sells by Donald J. Trump, with the most recent disclosed trade on July 1. The stock has declined 1.1% over the past eight sessions, from $40.45 to $40.01.
What To Watch
Indivior has not scheduled an earnings release in the near term. Investors will likely monitor the merger’s regulatory and shareholder approval progress, as well as broader market sentiment toward biopharma consolidations.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
INDV · Aug 3 session (5-min) · -5.65% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 15 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
7d agoYahoo FinanceBULLISH 65M&A
Indivior Q2 Earnings Call Highlights
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The t
7d agoTipRanksBULLISH 55M&A
Supernus and Indivior Announce Proposed Stock-for-Stock Merger
Supernus Pharmaceuticals ( ($SUPN) ) has shared an update. On August 3, 2026, Supernus Pharmaceuticals and Indivior Pharmaceuticals held a joint conference call and...
7d agoTipRanksBULLISH 55M&A
Indivior and Supernus announce tax-free merger of equals
The latest announcement is out from Indivior ( ($INDV) ). Indivior Pharmaceuticals, Inc. is a biopharmaceutical company focused on central nervous system disorders,...
7d agoInvestorsHubBULLISH 73Earnings
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook
Indivior beat second-quarter earnings and revenue estimates, raised its 2026 guidance and reported record SUBLOCADE sales, sending shares sharply higher in pre-market trading.
7d agoInvestorsHubBULLISH 73M&A
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement
Supernus beat second-quarter revenue estimates, raised its 2026 guidance and announced a merger with Indivior, sending shares sharply higher despite an earnings miss driven by a non-cash impairment charge.
7d agoMarketChameleonBULLISH 73Earnings
Indivior Delivers Record Q2 Results With 111% EBITDA Growth and Raises Full-Year Outlook
August 3, 2026
Indivior posts a record-breaking second quarter for 2026 marked by 111% EBITDA growth year-over-year, driven by outstanding SUBLOCADE performance and disciplined expense control. The company raises its full-year guidance and positions itself for a proposed merger with Supernus.
7d agoReutersBULLISH 58M&A
Supernus, Indivior merge to strengthen neuroscience drug portfolio
7d agoInvesting.com MarketsNEUTRAL 50General
Why is Indivior stock surging today?
Why is Indivior stock surging today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →